07:38 AM EDT, 08/05/2024 (MT Newswires) -- Axsome Therapeutics ( AXSM ) reported a Q2 loss of $1.67 per share, wider than $1.54 a year earlier.

Analysts polled by Capital IQ expected a loss of $1.33 per share.

Revenue for the quarter ended June 30 was $87.2 million, up from $46.7 million a year earlier.

Analysts polled by Capital IQ expected $86.9 million.

Cash and cash equivalents totaled $315.7 million as of June 30, down from $386.2 million as of Dec. 31.

Axsome shares were down 5.4% in recent Monday premarket activity.

Price: 79.89, Change: -4.53, Percent Change: -5.37